Is S-1 a Potential Game Changer in Adjuvant Therapy of Pancreatic Cancer?
There remains a lack of consensus on the optimal adjuvant therapy for pancreatic cancer. In general, chemoradiation is favored in the United States and gemcitabine based chemotherapy is favored in Europe. Both of these approaches have been shown by large prospective, randomized trials to improve disease free survivals and in some studies overall survival. We present the summary of three abstracts from the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting and discuss their potential impact on our clinical practice. Adjuvant oral chemotherapy with S-1 (Fukutomi et al., Abstract #4008) has now emerged as a promising alternative to the traditional gold standard of intravenous gemcitabine in a relatively large randomized phase III clinical trial. Another study by Yoshitomi et al. (Abstract #4056) examined the value of adjuvant chemotherapy with S-1 alone versus combination of S-1 and gemcitabine versus gemcitabine alone in a three arm phase II clinical trial (CAP-002 Study). In terms of biomarkers in pancreatic cancer, Neoptolemos et al. presented the impact of hENT1 tumor levels on the outcome of the patients with pancreatic cancer (Abstract #4006) who had received adjuvant chemotherapy with either 5-flurouracil or gemcitabine in the ESPAC trial.
Image: Composition and mechanism of action of S-1.
Neoptolemos JP, Stocken DD, Friess H, Bassi C et. al. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. N Engl J Med 2004;350:1200-10.
Oettle H, Post S, Neuhaus P, Gellert K et. al. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer. A Randomized Controlled Trial. JAMA. 2007;297:267-277
Neuhaus P, Riess H, Post S, Gellert K et. al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26: 2008 (May 20 suppl; abstr LBA4504).
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P. Adjuvant Chemotherapy with Fluorouracil plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. A Randomized Controlled Trial. JAMA. 0;0(10):1073-1081
Regine WF, Winter KA, Abrams RA, Safran H et al. Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A randomized Controlled Trial. JAMA. 2008; 299(9):1019-1026.
Uesaka K, Fukutomi A, Boku N, Kanemoto H et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 30: 2012 (suppl 34; abstr 145).
Fukutomi A, Uesaka K, Boku N et al. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31, 2013 (suppl; abstr 4008)
Chaulagain CP, Ng J, Goodman MD, Saif MW. Adjuvant therapy of pancreatic cancer. Journal of Pancreas, 2013 Mar 10;14(2):119-22
Yoshitomi H, Shimizu H, Yoshidome H. A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study). J Clin Oncol 31, 2013 (suppl; abstr 4056).
Neoptolemos JP, Greenhalf W, Ghaneh P et al. HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials. J Clin Oncol 31, 2013 (suppl; abstr 4006).
Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009 Mar; 18(3):335-48.
Park SR, Park MS, Park YL, Kim NK et. al. CYP2A6 genetic polymorphism as a predictive marker for clinical outcomes in patients (pts) with metastastic gastric carcinoma (MGC) treated with S-1 plus docetaxel. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4633
Ueno H, Ioka T, Ikeda M et al. Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. J Clin Oncol 2012.43.3680
Poplin E, Wasan H, Rolfe L et al. Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment. J Clin Oncol 31, 2013 (suppl; abstr 4007)
Kawada N, Uehara H, Katayama K et al. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. J Hepatobiliary Pancreat Sci. 2012 Nov; 19(6):717-22.
Saif MW. Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007.JOP. 2007 Mar 10;8(2):166-76.
Copyright (c) 2014 Chakra P Chaulagain, Janice Rothschild, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.